- The U.S. Food and Drug Administration (FDA) granted fast track designation to Reneo Pharmaceuticals' ( NASDAQ: RPHM ) medicine mavodelpar (REN001) for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency.
- LCHAD deficiency is one of the predominant genotypes in patients with long-chain fatty acid oxidation disorder (LC-FAOD), the company said in a press release on Tuesday.
- LCHAD deficiency is a rare disorder which prevents the body from converting certain fats to energy, mainly during periods without food. LC-FAOD is a group of rare genetic disorders characterized by impaired fat metabolism causing crises of energy production and chronic energy deficiency.
- "Receiving this Fast Track designation for a second indication continues to solidify mavodelpar as a potential therapeutic option for patients with rare mitochondrial disease," said Reneo's President and CEO Gregory Flesher.
- RPHM +5.56% to $2.85 premarket Jan. 31
For further details see:
Reneo stock rises on FDA fast track status for rare metabolic disorder drug